… ProQR to Present its Axiomer® RNA Editing Technology at the … & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation Presentation title: Development of RNA …
… ProQR Announces Top-Line Results from Phase 2/3 Illuminate … Daniel A. de Boer, Founder and CEO of ProQR Therapeutics. “ProQR was founded with the goal of developing RNA therapies … many are feeling in the community,” said Benjamin R. Yerxa, Chief Executive Officer at the Foundation Fighting …
… ProQR spins out all Dystrophic Epidermolysis Bullosa … and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … in a dedicated effort,” said Daniel A. de Boer, CEO at ProQR. “With this transaction we’ve now fully focused our …
… ProQR Announces Presentations at ECFS on Eluforsen for … LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … CFF Research Conference. Presentation at ECFS Conference ProQR will deliver a short talk (ePoster) and a poster …
… ProQR Announces Publication on QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Adamson, Ph.D., senior vice president of ophthalmology for ProQR. “The ongoing clinical trial of QR-110 in patients with …
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’